Core 03: Tumor Imaging Metrics

核心 03：肿瘤成像指标

• 批准号: 10062885
• 负责人: GORDON J HARRIS
• 金额: $ 17.85万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-10 至 2021-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10062885
• 关键词: 3-Dimensional; Cancer Center; Certification; Clinical Investigator; Clinical Trials; Clinical trial protocol document; Collection; Consultations; Dana-Farber Cancer Institute; Databases; Discipline of Nuclear Medicine; Enrollment; Faculty; General Hospitals; Guidelines; Home; Hospitals; Image; Institution; Knowledge; Lesion; Magnetic Resonance Imaging; Massachusetts; Measurement; Mission; Modality; Online Systems; Patient Care; Patients; Physicians; Positron-Emission Tomography; Protocols documentation; Radiology Specialty; Reporting; Research Personnel; Resource Sharing; Resources; Scanning; Secure; Services; Site; Specialist; Standardization; Time; Training; Training and Education; Woman; X-Ray Computed Tomography; cancer clinical trial; cancer imaging; clinical trial analysis; data access; imaging study; individual patient; medical schools; mid-career faculty; professor; radiologist; response; service member; statistics; treatment response; tumor; web site

Tumor Imaging Metrics Shared Resource Project Summary / Abstract The Tumor Imaging Metrics Core provides objective assessment of tumor response to treatment for patients enrolled in oncology clinical trials. All major radiological assessment criteria are supported including: RECIST (1.0 and 1.1), Cheson (2007 and 2009), IWCLL, RANO, PET SUV, PCWG2, Choi, 3D Volume, and irRC. For each patient, target and non-target lesions are selected according to the assessment criteria guidelines and are tracked longitudinally. Users are able to log into the website from anywhere at any time to access data and order a request for scan analysis. Quantitative analysis of CT, MR, and PET imaging studies are performed on a variety of modality-specific workstations. After scans are analyzed, the measurement results are reviewed and finalized by Harvard faculty radiologists and/or nuclear medicine physicians. Measurement results are stored in the Core database on a secure website and are viewable online by authorized trial staff. The quantitative measurements are used to determine tumor response to treatment and ultimately guide patient care. Summary statistics for the trial are presented as well as individual patient measurements. Rates for services are very reasonable compared to other options available from outside DF/HCC.

肿瘤成像指标共享资源 项目概要/摘要 肿瘤成像指标核心为患者提供肿瘤对治疗反应的客观评估 参加肿瘤学临床试验。支持所有主要放射学评估标准，包括： RECIST （1.0 和 1.1）、Cheson（2007 和 2009）、IWCLL、RANO、PET SUV、PCWG2、Choi、3D Volume 和 irRC。为了 根据评估标准指南选择每个患者、目标病灶和非目标病灶并 纵向跟踪。用户可以随时随地登录网站访问数据和 订购扫描分析请求。对 CT、MR 和 PET 成像研究进行定量分析 各种特定于模态的工作站。分析扫描后，审查测量结果 并由哈佛大学放射科医生和/或核医学医师最终确定。测量结果为 存储在安全网站上的核心数据库中，授权试验人员可以在线查看。这 定量测量用于确定肿瘤对治疗的反应并最终指导患者 关心。提供了试验的汇总统计数据以及个体患者的测量结果。价格为 与 DF/HCC 外部提供的其他选项相比，服务非常合理。